Oncology Pharmacy Clinical Sessions (Cert # L249027)

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as providers of continuing pharmacy education.

These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:

• Management of diffuse large B-cell lymphoma
• Management of amyloidosis

Board certified pharmacists are eligible to receive up to 4 contact hours of recertification credit for completing this course. To earn recertification credit, learners must review the course content and successfully complete the online assessments by the deadline.

ASHP provides an opportunity for remediation. Participants who are unsuccessful with the first assessment attempt may take a second assessment. The second assessment is included at no additional cost.

ACCP and ASHP is approved by BPS as a provider for the recertification of BCOP.

Emerging Therapies and Clinical Controversies in the Management of Diffuse Large B-Cell Lymphoma
ACPE #: 0217-9999-23-075-H01-P

• Assess clinical data evaluating the integration of new therapies into the first-line treatment of diffuse large B-cell lymphoma (DLBCL).
• Compare central nervous system prophylaxis strategies for high-risk patients with DLBCL.
• Identify considerations for sequencing new therapeutic modalities for relapsed/refractory DLBCL.
• Apply recently published literature evaluating the role of chimeric antigen receptor T-cell therapies in DLBCL.
• Recommend supportive care measures for managing unique toxicities associated with newer therapies for DLBCL. 

Amyloidosis: Updates and Clinical Management
ACPE #: 0217-9999-23-076-H01-P

• Develop appropriate counseling points on therapy recommendations for amyloidosis.
• Identify initiation of therapy for light-chain (AL) amyloidosis patients as either first-line or relapsed/refractory disease.
• Compose a treatment plan for a patient with transthyretin-related (ATTR) amyloidosis based on recommendations from current guideline recommendations.
• Interpret the financial impact of therapy of disease modifying agents and supportive care therapies in amyloidosis.
• Prepare best supportive care recommendations and monitoring for patients with amyloidosis.

Faculty bios

Katie Gatwood, PharmD, BCOP
Stem Cell Transplant & Cellular Therapy Clinical Pharmacist Specialist
Vanderbilt University Medical Center
Nashville, Tennessee 

Shawn Griffin, PharmD, BCOP
Assistant Clinical Professor
University of California, Irvine
Irvine, California 

Mitchell E. Hughes, PharmD, BCOP*
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy, Lymphoma Program and Lymphoma Translational Research
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 

Oxana Megherea, PharmD, BCOP
Clinical Pharmacy Specialist, Hematology/Oncology/Cellular Therapy, Multiple Myeloma Program
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania 

Donald C. Moore, PharmD, BCOP, DPLA*
Clinical Oncology Pharmacy Manager
Levine Cancer Institute
Charlotte, North Carolina 

Breanna Taylor, PharmD, BCOP
Clinical Pharmacy Specialist – Outpatient Non-Malignant and Malignant Hematology/Transplantation and Cellular Therapy
Novant Health
Charlotte, North Carolina

*Content Matter Experts

Elizabeth M. Kelley, PharmD, BCOP, BCPS
Tracy Joy Lim, PharmD, BCOP, BCPS
Onyebuchi Ononogbu, PharmD, BCOP
Anna E. Shook, PharmD, BCPS, BCOP

Janet Bramell, PharmD, BCPS, BCOP
Chun Kit Chung, BPharm, MEDM, BCOP
Bryan Feagan, PharmD, BCPS, BCACP, BCOP
Baher Ghanem, BScPharm, BCOP
Elisabeth Hebert, BPharm, M.Sc, BCOP
Evan Kam, PharmD, BCOP, BCSCP
Elle Kim, RPh, BCPS, BCOP
Mijeong Kim, PharmD, BCPS, BCOP
Kimberley Kolb, BS, BCOP
Tristan Lindfelt, PharmD, BCPS, BCOP
Teresa Rushing, PharmD, BCPS, BCOP
Barbara Yim, PharmD, BCOP
Kelsey Zielke, PharmD, BCPS, BCOP

In accordance with our accreditor’s Standards of Integrity and Independence in Accredited Continuing Education, ASHP requires that all individuals in control of content disclose all financial relationships with ineligible companies. An individual has a relevant financial relationship if they have had a financial relationship with an ineligible company in any dollar amount in the past 24 months and the educational content that the individual controls is related to the business lines or products of the ineligible company. 

An ineligible company is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The presence or absence of relevant financial relationships will be disclosed to the activity audience. 

The following persons in control of this activity’s content have relevant financial relationships:

• Katie Gatwood – Speakers bureau: Jazz, Kite, Sanofi; Advisory board: Astellas, BioLineRx; Grant funding: AstraZeneca.
• Mitchell Hughes – Research funding: Acerta Pharma and HOPA; Advisory board: AstraZeneca, Genzyme, Janssen, Abbvie, Karyopharm
• Donald Moore – Advisory board: AstraZeneca, Janssen, Pfizer

Activities consist of audio/video/PDF files, an attestation statement, and activity evaluation. Learners must review all content and complete the attestation statement and course evaluation to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

ACCP and ASHP collaborate on oncology pharmacy activities.